Genzyme Corp.  (GENZ) Trade Now »     Rate GENZ  -  Discuss GENZ  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

GENZ: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

FDA Calendar: Allergan's New Rx for Eyelashes GENZ

75%

-0.94% in 11 days FDA Calendar: Allergan's New Rx for Eyelashes The accompanying table [click to enlarge] includes an updated FDA calendar of 65 expected decision dates included in the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, with six companies listed in red with overdue decisions and the possibility for five decisions during the coming week. Click here for my previous FDA calendar articles and below is a review of recent decisions + a preview of the coming week: 1.) Allergan (AGN) received FDA approval on Friday for Latisse (bimatoprost solution 0.0 ... Continue reading »

FDA Calendar: A Weekly Update GENZ

75%

+0.09% in 23 days (closed on 12/28/08) FDA Calendar: A Weekly Update The accompanying table [click to enlarge] presents an updated calendar of 73 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index. Below is a summary of the FDA action over the past week. 1.) ViroPharma (VPHM) – Filed a sBLA on 12/1/08 to expand use of Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema [HAE], which is already FDA approved for regular use in the prevention of angioedema attacks in adolescent and adult patients with HAE. Standa ... Continue reading »

Full Calendar of FDA Decisions GENZ

75%

+5.01% in 5 days (closed on 12/05/08) Full FDA Calendar of Decision Dates The accompanying table [click to enlarge] includes an updated calendar of 73 expected FDA decision dates. Click here for my previous articles and FDA calendars , including several companies with expected decisions before year-end expected to have major stock price impacts, but keep in mind the backlog of delayed decisions that is building means that none of the dates are certain to produce final decisions. Genzyme (GENZ) could hear back from the FDA as early as Monday for approval of Myozyme at the 2,000L b ... Continue reading »

Updated 3-Month FDA Calendar GENZ

75%

+0.00% in 1 day (closed on 11/30/08) Updated 3-Month FDA Decision Calendar The accompanying table includes an updated calendar of FDA decisions expected to occur within the next three months. Most recently, the FDA continued its tough stance toward new antibiotic approvals and issued a complete response letter for ceftobiprole to Johnson & Johnson (JNJ) and its Swiss partner, Basilea Pharma ( Switzerland: BSLN ) – sending the latter down sharply to new lows on Wednesday with a sharp rebound of 30% by the end of the week, but still down by about 43% in the last year. The FDA cited concern ... Continue reading »

ETFI Global Healthcare Sector PerformIdex GENZ

75%

-12.62% in 21 days (closed on 11/29/08) ETFI Global Healthcare Sector PerformIdex The accompanying table presents the top six rated companies with market caps of at least $250 million (USD) from each of the eight ETFI healthcare indexes (which include a database of about 320 companies) as equally-weighted components in the ETFI Global Healthcare Sector PerformIdex of 48 companies. 1.) ETFI Global Hospitals 2.) ETFI New Drug Regulatory Catalyst 3.) ETFI Global AnimalBiz 4.) ETFI Health Benefit Providers 5.) ETFI Cosmetic & Reconstructive Medicine 6.) ETFI G ... Continue reading »

From the Blogosphere

FDA Calendar: Allergan's New Rx for Eyelashes

75%

The accompanying table [click to enlarge] includes an updated FDA calendar of 65 expected decision dates included in the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, with six companies listed in red with overdue decisions and the possibility for five decisions during the coming week. Click here for my previous FDA calendar articles and below is a review of recent decisions + a preview of the coming week: 1.) Allergan (AGN) received FDA approval on Friday for Latisse (bimatoprost solution 0.03%) as a cosmetic medicine treatment which represents the first and only FDA-approved pr... Continue reading »

Nasdaq Market Wrap - 5 Jan 2009

N/A

Support at 1150 for the emini nasdaq (@nq). The Index is testing the resistance at 1250. Many are betting on a failed breakout. Next resistance at 1400. I think the market will continue the rebound although general conditions remain pretty weak for the moment. Very interesting, most stocks are trading above their 50-day moving average. AKAM, AMGN, GOOG, JAVA, JNPR, RIMM, SBUX, TLAB have printed a 20-day high. JNPR has printed 5 consecutive up closes. In the Figure you can see a summary of the trend conditions of the Index stocks. I used the 20, 50, 100 and 200 days moving average of the... Continue reading »

Nasdaq Market Wrap - 5 Jan 2009

Support at 1150 for the emini nasdaq (@nq). The Index is testing the resistance at 1250. Many are betting on a failed breakout. Next resistance at 1400. I think the market will continue the rebound although general conditions remain pretty weak for the moment. Very interesting, most stocks are trading above their 50-day moving average. AKAM, AMGN, GOOG, JAVA, JNPR, RIMM, SBUX, TLAB have printed a 20-day high. JNPR has printed 5 consecutive up closes. In the Figure you can see a summary of the trend conditions of the Index stocks. I used the 20, 50, 100 and 200 days moving average of the... Continue reading »

Nasdaq Market Wrap 29 Dec

N/A

GILD is the only stock trading above the 3 moving averages (20, 50, 100). In the Figure you can see a summary of the trend conditions of the Index stocks. I used the 20, 50, 100 and 200 days moving average of the close. The background is Green when the close is > than the moving average. Red when it is below and yellow when it crosses. + and - indicate the slope of the moving average. RANGE ANALYSIS I have also programmed Tradestation Radarscreen to display: - range of the past 20 trading sessions (%); - % from the lowest close of the past 20 trading session. The cell is RED if the close of tod... Continue reading »

Nasdaq Market Wrap 29 Dec

GILD is the only stock trading above the 3 moving averages (20, 50, 100). In the Figure you can see a summary of the trend conditions of the Index stocks. I used the 20, 50, 100 and 200 days moving average of the close. The background is Green when the close is > than the moving average. Red when it is below and yellow when it crosses. + and - indicate the slope of the moving average. RANGE ANALYSIS I have also programmed Tradestation Radarscreen to display: - range of the past 20 trading sessions (%); - % from the lowest close of the past 20 trading session. The cell is RED if the close of tod... Continue reading »

Trade GENZ Now
and Get 30 Free Trades »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.